Discovery of Small Molecule RIP1 Kinase Inhibitors for the Treatment of Pathologies Associated with Necroptosis
摘要:
Potent inhibitors of RIP1 kinase from three distinct series, 1-aminoisoquinolines, pyrrolo[2,3-b]pyridines, and furo[2,3-d]pyrimidines, all of the type II class recognizing a DLG-out inactive conformation, were identified from screening of our in-house kinase focused sets. An exemplar from the furo[2,3-d]pyrimidine series showed a dose proportional response in protection from hypothermia in a mouse model of TNF alpha induced lethal shock.
[EN] KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASES
申请人:ABBOTT LAB
公开号:WO2003080064A1
公开(公告)日:2003-10-02
The present application is directed to pyrazolopyrimidine and furopyrimidine analogs of the formula (I), wherein the substituents are as defined herein, which are useful as kinase inhibitors.
Discovery of Small Molecule RIP1 Kinase Inhibitors for the Treatment of Pathologies Associated with Necroptosis
作者:Philip A. Harris、Deepak Bandyopadhyay、Scott B. Berger、Nino Campobasso、Carol A. Capriotti、Julie A. Cox、Lauren Dare、Joshua N. Finger、Sandra J. Hoffman、Kirsten M. Kahler、Ruth Lehr、John D. Lich、Rakesh Nagilla、Robert T. Nolte、Michael T. Ouellette、Christina S. Pao、Michelle C. Schaeffer、Angela Smallwood、Helen H. Sun、Barbara A. Swift、Rachel D. Totoritis、Paris Ward、Robert W. Marquis、John Bertin、Peter J. Gough
DOI:10.1021/ml400382p
日期:2013.12.12
Potent inhibitors of RIP1 kinase from three distinct series, 1-aminoisoquinolines, pyrrolo[2,3-b]pyridines, and furo[2,3-d]pyrimidines, all of the type II class recognizing a DLG-out inactive conformation, were identified from screening of our in-house kinase focused sets. An exemplar from the furo[2,3-d]pyrimidine series showed a dose proportional response in protection from hypothermia in a mouse model of TNF alpha induced lethal shock.